Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | DARA-KRd with MRD-based response-adapted therapy in newly diagnosed myeloma

Luciano Costa • 15 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Lenalidomide
MASTER

Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, discusses the MASTER study (NCT03224507) which investigated the use of sequential daratumumab, carfilzomib, lenalidomide and dexamethasone (DARA-KRd) induction in newly diagnosed multiple myeloma with therapy duration guided by measurable residual disease (MRD). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Luciano Costa

1:45
Challenges for community clinicians treating multiple myeloma
Luciano Costa • 11 Dec 2023
2:02
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Luciano Costa • 11 Dec 2023
2:40
Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma
Luciano Costa • 11 Dec 2023
3:38
Outcomes for patients with multiple myeloma who have had first-line monoclonal antibody exposure
Luciano Costa • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals